Immutep Limited Announces Positive Data from INSIGHT-003 Trial
Mature Data Shows Excellent Results in NSCLC Patients
Sydney, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company, has released positive data from the INSIGHT-003 Phase I trial.
Immutep’s latest data from patients with a minimum follow-up of 22 months has surpassed historical controls and exceeded expectations. With a Median Overall Survival of 32.9 months and a median Progression Free Survival of 12.7 months, the results are promising. Furthermore, the 24-month Overall Survival rate of 81.0% is a significant improvement compared to previous treatments.
The safety profile of the treatment remains favorable, with no new safety signals reported. These positive results have garnered excitement among researchers and clinicians, as they pave the way for further advancements in cancer treatment.
INSIGHT-003, which is nearing completion of enrollment, evaluates eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients. This trial aims to assess the efficacy and safety of this novel combination therapy.
Prof. Dr. Salah-Eddin Al-Batran of the Frankfurt Institute of Clinical Cancer Research (IKF) and project lead for INSIGHT-003 expressed optimism about the results, stating, “The mature survival data, along with the favorable safety profile in treating patients with non-squamous NSCLC, is very encouraging.”
Overall, the findings from the INSIGHT-003 trial suggest a promising future for cancer patients, particularly those with NSCLC who have limited treatment options. Immutep’s innovative approach to cancer immunotherapy is setting new standards in patient care and treatment outcomes.
How Will This Impact Me?
If you or a loved one are facing a diagnosis of non-squamous non-small cell lung cancer, the positive results from the INSIGHT-003 trial offer hope for improved treatment options. The combination therapy being evaluated in the trial has shown significant improvement in survival rates and overall response rates, potentially leading to better outcomes for patients in the future.
How Will This Impact the World?
The successful results from the INSIGHT-003 trial have the potential to revolutionize the treatment of non-squamous non-small cell lung cancer on a global scale. By demonstrating improved survival rates and efficacy compared to standard treatments, Immutep’s novel immunotherapy approach could change the landscape of cancer care and improve outcomes for patients worldwide.
Conclusion
The positive data from the INSIGHT-003 trial marks a significant milestone in the development of innovative cancer therapies. Immutep’s commitment to advancing LAG-3 immunotherapies for cancer patients has the potential to reshape the treatment landscape and offer new hope to those facing challenging diagnoses. As research continues to progress, the future looks brighter for patients with NSCLC and other types of cancer.
